Quinolone Efflux Pumps Play a Central Role in Emergence of Fluoroquinolone Resistance in Streptococcus pneumoniae
Open Access
- 1 January 2006
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (1) , 310-317
- https://doi.org/10.1128/aac.50.1.310-317.2006
Abstract
The preferential use of older antimicrobial agents is, in general, sound public health policy and is meant to maintain susceptibility to newer agents. In the case of fluoroquinolones, however, this strategy is flawed and may actually hasten the spread of Streptococcus pneumoniae strains resistant to newer members of the class. In a mouse thigh infection model, we were unable to isolate clones of pneumococci resistant to the newer fluoroquinolone levofloxacin at 2 × or 4 × the baseline MIC. An initial exposure in vivo to the older agent, ciprofloxacin, allowed straightforward selection of clones resistant to levofloxacin in a subsequent experiment. The original ciprofloxacin exposure generated clones without changes in the parC / E and gyrA / B quinolone target sites almost exclusively but did allow overexpression of a reserpine-responsive pump. While this caused only minimal change in the levofloxacin MIC (0.6 mg/liter to 0.8 mg/liter), it allowed a major change in the mutational frequency to resistance for levofloxacin (8.5 to approximately 1/10 4.5 ), which allowed levofloxacin-resistant clones to be isolated in a subsequent in vivo experiment. The reason underlying ciprofloxacin's propensity to select for pump-overexpressed clones is likely related to its hydrophilicity. To preserve the susceptibility of Streptococcus pneumoniae to newer members of the class of quinolones, use of ciprofloxacin for community-acquired respiratory infections should be minimized.Keywords
This publication has 22 references indexed in Scilit:
- Pharmacodynamics of Levofloxacin and Ciprofloxacin in a Murine Pneumonia Model: Peak Concentration/MIC versus Area under the Curve/MIC RatiosAntimicrobial Agents and Chemotherapy, 2003
- Widespread Use of Fluoroquinolones Versus Emerging Resistance in PneumococciClinical Infectious Diseases, 2002
- Pharmacodynamics of the New Fluoroquinolone Gatifloxacin in Murine Thigh and Lung Infection ModelsAntimicrobial Agents and Chemotherapy, 2002
- Importance of Local Variations in Antibiotic Consumption and Geographical Differences of Erythromycin and Penicillin Resistance in Streptococcus pneumoniaeJournal of Clinical Microbiology, 2002
- Does the Dose Matter?Clinical Infectious Diseases, 2001
- Need for Annual Surveillance of Antimicrobial Resistance in Streptococcus pneumoniae in the United States: 2-Year Longitudinal AnalysisAntimicrobial Agents and Chemotherapy, 2001
- Community‐Acquired Pneumonia in Adults: Guidelines for ManagementClinical Infectious Diseases, 1998
- State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and MenClinical Infectious Diseases, 1998
- Rapid stereospecific high-performance liquid chromatographic determination of levofloxacin in human plasma and urineJournal of Pharmaceutical and Biomedical Analysis, 1997
- Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equationsJournal of Pharmacokinetics and Biopharmaceutics, 1978